Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Simply Wall St.02-28

AdvertisementRecent share move and business snapshot Ascentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614149338?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-28 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614149338","market":"sg","top_or_hot":-1,"title":"Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent share move and business snapshot Ascentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 17:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent share move and business snapshot Ascentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1","article_id":"2614149338","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614149338","pubTimestamp":1772271115,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent share move and business snapshot\nAscentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly 26.9% over the past 3 months, drawing attention to its clinical stage biotech profile.\nSee our latest analysis for Ascentage Pharma Group International.\nLooking beyond the latest move, the share price has recorded a 4.9% decline over the past month and a 26.9% decline over the past quarter, while the 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"在近期股价波动后评估亚盛医药集团国际（联交所：6855）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"AdvertisementRecent share move and business snapshot Ascentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly 26.9% over the past 3 months, drawing attention to its clinical stage biotech profile. See our latest analysis for Ascentage Pharma Group International. Looking beyond the latest move, the share price has recorded a 4.9% decline over the past month and a 26.9% decline over the past quarter, while the 1 year total shareholder return of 24.9% and 3 year total shareholder return of 78.67% indicate that longer term holders have seen stronger outcomes even as recent momentum has faded. If this kind of volatility has you comparing ideas across biotech and pharma, it could be a good moment to see what stands out among 113 healthcare AI stocks. So with recent share price weakness, an intrinsic value estimate that screens at a steep discount, and a price target sitting far above the last close, is there a genuine buying opportunity here, or is the market already pricing in future growth? Most Popular Narrative: 48.6% Undervalued At a last close of HK$46.90 versus a widely followed fair value estimate of HK$91.17, the current price sits well below that narrative benchmark, and the gap largely comes down to how future growth, margins, and required returns are modeled.  The assumed bearish price target for Ascentage Pharma Group International is HK$51.97, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Ascentage Pharma Group International's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.  Read the complete narrative. Want to see how a cautious price target still supports a much higher fair value? Revenue trajectories, margin shifts, and a rich future earnings multiple all play a part, but the exact mix of assumptions may surprise you. Result: Fair Value of HK$91.17 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, strong Olverembatinib and Lisaftoclax data, or further Takeda related milestones, could challenge the bearish case and push analysts to revisit their assumptions. Find out about the key risks to this Ascentage Pharma Group International narrative. Another view on valuation Those DCF style fair values that point to heavy upside sit awkwardly next to the current sales based valuation. Ascentage trades on a P/S of 38.7x versus 13.1x for the Hong Kong Biotechs industry and 13.6x for peers. The fair ratio of 14.3x suggests a market multiple that could drift lower over time. Is the discount to fair value big enough to offset that kind of multiple risk? See what the numbers say about this price — find out in our valuation breakdown. SEHK:6855 P/S Ratio as at Feb 2026Next Steps With mixed signals across valuation, growth expectations and sentiment, this is the kind of setup where it pays to review the numbers yourself and move decisively, especially when our work highlights 3 key rewards and 1 important warning sign. Looking for more investment ideas? If this analysis has sparked new questions, do not stop here. Use the same disciplined approach to compare fresh ideas and keep your watchlist sharp.  Target potential mispricings by scanning companies that look cheap on quality and fundamentals with our 220 high quality undervalued stocks. Prioritise resilience by focusing on companies with sturdier finances using the solid balance sheet and fundamentals stocks screener (370 results). Shape a more income focused watchlist by reviewing the 445 dividend fortresses that could complement growth oriented positions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614149338","isCrawlerRequest":true}